SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-010336
Filing Date
2020-08-11
Accepted
2020-08-11 16:35:17
Documents
45
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20200630x10q.htm 10-Q 1329339
2 EX-10.1 apre-20200630ex1010cbc2e.htm EX-10.1 431857
3 EX-31.1 apre-20200630ex311f1737c.htm EX-31.1 9728
4 EX-31.2 apre-20200630ex312626cb0.htm EX-31.2 9719
5 EX-32.1 apre-20200630ex3215847fd.htm EX-32.1 6710
6 EX-32.2 apre-20200630ex3224c8d51.htm EX-32.2 6703
  Complete submission text file 0001558370-20-010336.txt   3516549

Data Files

Seq Description Document Type Size
7 EX-101.INS apre-20200630.xml EX-101.INS 395597
8 EX-101.SCH apre-20200630.xsd EX-101.SCH 22384
9 EX-101.CAL apre-20200630_cal.xml EX-101.CAL 31007
10 EX-101.DEF apre-20200630_def.xml EX-101.DEF 41480
11 EX-101.LAB apre-20200630_lab.xml EX-101.LAB 200225
12 EX-101.PRE apre-20200630_pre.xml EX-101.PRE 136905
Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 201092910
SIC: 2834 Pharmaceutical Preparations